Shuttle Pharmaceuticals Holdings (SHPH) Research & Development (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Research & Development of $267240.0 for Q1 2026, down 83.02% year-over-year from $1.6 million in Q1 2025, and down 51.83% quarter-over-quarter from $554831.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Research & Development (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Research & Development history runs 6 years deep, the most recent figure standing at $267240.0 for Q1 2026.
- In Q1 2026, Research & Development fell 83.02% year-over-year to $267240.0; the TTM figure through Mar 2026 stood at $2.7 million (down 40.18% YoY), while the FY2025 annual figure was $4.1 million, up 12.05% from the prior year.
- Research & Development for Q1 2026 stood at $267240.0, down from $554831.0 in the prior quarter.
- The five-year high for Research & Development was $1.6 million in Q1 2025, with the low at -$1436.0 in Q4 2022.
- The 5-year median for Research & Development is $693356.0 (2023), against an average of $734605.3.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 100.32% in 2022, then surged 48383.84% in 2023.
- Shuttle Pharmaceuticals Holdings' Research & Development stood at -$1436.0 in 2022, then soared by 48383.84% to $693356.0 in 2023, then soared by 46.94% to $1.0 million in 2024, then plunged by 45.54% to $554831.0 in 2025, then plunged by 51.83% to $267240.0 in 2026.
- Business Quant data shows SHPH's Research & Development at $267240.0 in Q1 2026, $554831.0 in Q4 2025, and $900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.83 Mn | 1.83 Mn | - | 267,240.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 267,240.00 |
| Dec 31, 2025 | 554,831.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.57 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Dec 31, 2023 | 693,356.00 |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 839,665.00 |
| Mar 31, 2023 | 921,801.00 |
| Dec 31, 2022 | -1,436.00 |
| Sep 30, 2022 | 669,038.00 |
| Jun 30, 2022 | 83,868.00 |
| Mar 31, 2022 | 295,915.00 |
| Dec 31, 2021 | 442,124.00 |
| Sep 30, 2021 | 186,958.00 |